Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma's Q3 revenue and net loss missed analyst estimates. 46% of Phase 2a patients discontinued treatment in imdusiran trials. The company continues litigation against Moderna and Pfizer/BioNTech over LNP technology. Favorable ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026. Decrease in R&D expenses due to restructuring. Current analyst rating is “buy” with a median 12-month price target of $5.00.
)
Overview
- Arbutus Q3 revenue and net income missed analyst expectations
- Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials
- Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology
Outlook
- Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026
- 46% of Phase 2a patients discontinued treatment, showing potential efficacy of imdusiran
Result Drivers
- COST REDUCTIONS - Decrease in R&D expenses due to restructuring and focus on imdusiran and AB-101
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Miss $500,000 $1.27
Revenue mln (3
Analysts
)
Q3 Net Miss -$7.70 -$6.94
Income mln mln (2
Analysts
)
Q3 Cash $93.70
& mln
Investme
nts
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Arbutus Biopharma Corp is $5.00, about 3.2% above its November 12 closing price of $4.84
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
